Inhibikase Therapeutics, Inc. (the “Issuer”)
| (b) | Address of Issuer’s Principal Executive Offices |
3350 Riverwood Parkway SE, Suite 1900
Atlanta, GA 30339
Item 2.
This statement is filed on behalf of SP IKT Holdings LLC and SP Soleus Holdings LLC (each, a “Reporting Person”).
| (b) | Address of Principal Business Office, or if none, Residence |
The address of the principal business office of each of the Reporting Persons is
20 Horseneck Ln.
Greenwich, CT 06880
Each of the Reporting Persons is a limited liability company organized under the laws of the State of Delaware.
| (d) | Title of Class of Securities |
Common Stock, par value $0.001 per share (“Common Stock”)
45719W205
Item 3. | If this statement is filed pursuant to §240.13d-1(b) or 240.13d.2(b) or (c), check whether the person filing is a: |
Not Applicable.
The Reporting Persons are either holding companies without operations, or are principally engaged in the business of investment management or making, purchasing, selling and holding investments. SP Soleus Holdings LLC is the sole Member of SP IKT Holdings LLC. SP Soleus Holdings LLC is managed by a four-member board of managers, which currently includes Charles A. Davis, Stephen Friedman, David J. Wermuth and Christopher Timchak.
Action by the board of managers is by simple majority vote. No individual manager on the board of managers has voting or dispositive control over the reported securities and, therefore, no individual manager has or shares beneficial ownership of such securities and this Statement shall not be construed as an admission of beneficial ownership that any individual manager of the Reporting Person is a beneficial owner of any of the securities covered by this Statement.